Longueuil, Canada

André B Charette

This inventor holds 2 USPTO granted patents. Top assignees: Infinity Pharmaceuticals, Inc., Valorisation-Recherche, Limited Partnership. Active years: 2011-2014.


% Patents Active = 50.0

Average Co-Inventor Count = 4.5

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2011-2014

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of André B Charette

Introduction

André B Charette is a notable inventor based in Longueuil, Canada. He has made significant contributions to the field of chemistry, particularly through his innovative patents. With a total of two patents to his name, Charette's work has implications in various scientific applications.

Latest Patents

Charette's latest patents include novel derivatives of cyclopamine, which are designed to enhance its therapeutic potential. The invention provides a new formula for cyclopamine analogs that could lead to advancements in medicinal chemistry. Additionally, he has developed phosphonium salt derivatives, which encompass a range of compounds with specific formulas that may have various applications in chemical synthesis.

Career Highlights

Throughout his career, Charette has worked with prominent companies such as Infinity Pharmaceuticals, Inc. and Valorisation-Recherche, Limited Partnership. His experience in these organizations has allowed him to collaborate on groundbreaking research and development projects.

Collaborations

Charette has collaborated with esteemed colleagues, including Brian C Austad and Mark L Behnke. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

André B Charette's innovative work in the field of chemistry, particularly through his patents, showcases his significant contributions to scientific research. His collaborations and career experiences further highlight his impact on the industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…